Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Xermelo Approved for Tumor-Related Diarrhea

Drug will treat a condition called carcinoid syndrome diarrhea

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, March 1, 2017 (HealthDay News) -- Xermelo (telotristat ethyl) tablets have been approved by the U.S. Food and Drug Administration to treat adults with carcinoid syndrome diarrhea, one of a collection of symptoms related to rare carcinoid tumors.

Most of these slow-growing tumors are found in the gastrointestinal tract, the agency said in a news release. Carcinoid syndrome occurs in fewer than 10 percent of people with carcinoid tumors, commonly after the tumor has spread to the liver. The tumor releases an excess amount of the hormone serotonin, leading to diarrhea.

Complications can include weight loss, malnutrition, dehydration and an imbalance of electrolytes.

Xermelo, taken three times daily with food, is designed to inhibit production of serotonin by carcinoid tumors, the FDA said.

The drug was evaluated in clinical studies involving 90 adults with carcinoid syndrome diarrhea, comparing results from those treated with the drug versus a placebo. The agency warned that people given a higher-than-recommended dose developed severe constipation, and one required hospitalization. Any Xermelo user who develops severe constipation or abdominal pain should stop the drug and contact a doctor, the FDA said.

Xermelo is produced by Lexicon Pharmaceuticals, based in Woodlands, Texas.

More information

Visit the FDA to to learn more.


Last Updated: